Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo-Reference-Cited by-同舟云学术

Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo

Published:2018-04-25 Issue:7 Volume:17 Page:1540-1553
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Song Mengqiu,Liu Xuejiao,Liu Kangdong,Zhao Ran,Huang Hai,Shi Yuanyuan,Zhang Man,Zhou Silei,Xie Hua,Chen Hanyong,Li Yin,Zheng Yan,Wu Qiong,Liu Fangfang,Li Enmin,Bode Ann M.,Dong Zigang,Lee Mee-Hyun

Funder

HHS | National Institutes of Health (NIH)

Key Program of Henan Province, China

National Natural Science Foundation of China (NSFC)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy;Acta Pharmaceutica Sinica B;2024-09

2. Targeting Peroxisome Proliferator-Activated Receptor-β/δ, Reactive Oxygen Species and Redox Signaling with Phytocompounds for Cancer Therapy;Antioxidants & Redox Signaling;2024-08-01

3. Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer;Biomedicine & Pharmacotherapy;2024-07

4. Synthesis and Application of a pH-Responsive Functional Metal–Organic Framework: In Vitro Investigation for Delivery of Oridonin in Cancer Therapy;Molecules;2024-06-04

5. Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation;Scientific Reports;2024-04-22